---

title: "Relationships Between Fatigue, Cognitive Function, and Upright Activity in a Randomized Trial of Oxaloacetate for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome"
tags:
- âž• 2025-12-25
- ðŸ’Š Treatment
created: '2025-09-23'
published: '2025-09-23'

---


<details>
<summary>Vernon et al. (2025)</summary>

- **Authors:** Suzanne D Vernon, Candace Rond, Yifei Sun, Shad Roundy, Jennifer Bell, Bella Rond, David Kaufman, Alan Brian Cash, Brayden Yellman, Lucinda Bateman.
- **Institutes:** Bateman Horne Center, Salt Lake City, United States; University of Utah, Salt Lake City, Utah, United States; Center for Complex Diseases, Seattle, Washington, United States; Terra Biological LLC, San Diego, California, United States.
- **Publisher:** Front. Neurol. (Frontiers in Neurology)
- **Link:** [DOI](https://doi.org/10.3389/fneur.2025.1691147)
- **What was researched?**
This randomized, controlled trial investigated the effects of the metabolic compound oxaloacetate (OAA) ðŸ’Š on self-reported fatigue, objective cognitive function, and time spent in upright activity (UP Time) in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The study's primary aim was to understand the interrelationships between these three key symptoms and how they respond to treatment.
- **Why was it researched?**
ME/CFS is a complex disease marked by fatigue, cognitive impairment, and physical dysfunction, but the connections between these core symptoms and their responsiveness to treatment are not well understood. Oxaloacetate (OAA) ðŸ’Š had previously shown potential for reducing fatigue symptoms in ME/CFS, prompting this study to explore its impact across multiple, essential domains of the illness, particularly its potential mitochondrial and neuroprotective effects.
- **How was it researched?**
This was a 90-day, randomized, double-blind, controlled trial involving 82 adults with ME/CFS. Participants were randomly assigned to receive either 2,000 mg/day of Oxaloacetate (OAA) ðŸ’Š or a control of 2,000 mg of rice flour. Fatigue (Chalder Fatigue Questionnaire), cognitive function (DANA Brain Vital), and UP Time were assessed at baseline and three follow-up visits. The data were analyzed using linear mixed-effects models to determine the associations and treatment effects.
- **What has been found?**
The OAA ðŸ’Š group showed significantly greater improvement in cognitive function compared to the control group at the 60-day mark (Visit 3, $p = 0.034$). Higher fatigue was strongly associated with reduced cognitive gains only in the OAA-treated group ($\beta = â€“0.34, p < 0.0001$). UP Time showed a small increase in the OAA group, reaching significance at the 30-day mark ($p = 0.044$), but fatigue was not a strong predictor of this change.
- **Discussion:**
The authors highlight that the strong connection, or "coupling," between fatigue and cognition observed specifically in the OAA ðŸ’Š group suggests that OAA may be targeting a mechanism that links these two symptoms. They note that while differences in "responder status" (patients meeting specific improvement criteria) between the groups did not reach statistical significance, the trends support a benefit of OAA. The findings underscore the critical need to use multiple, multidimensional outcome measures (like fatigue, cognition, and physical activity) in ME/CFS clinical trials.
- **Conclusion & Future Work:**
The study concludes that OAA ðŸ’Š supplementation was associated with improved cognitive performance and a small increase in upright activity time in the ME/CFS participants. The strong fatigueâ€“cognition coupling found in OAA-treated participants suggests a potentially targetable sub-phenotype of the illness. The authors recommend conducting more research and trials focused on metabolic interventions like OAA ðŸ’Š in ME/CFS.
- **Summary:**
This research provides evidence that Oxaloacetate (OAA) ðŸ’Š may selectively improve cognitive function and modestly increase time spent upright in a subset of ME/CFS patients. The finding that high fatigue dampened cognitive gains specifically in the OAA ðŸ’Š group, known as "fatigueâ€“cognition coupling," is a significant novel observation that suggests OAA's action may be tied to a specific biological pathway linking these two core symptoms. Although OAA's effect was not universally significant across all measures, this study supports the exploration of metabolic approaches for ME/CFS treatment and reinforces the necessity of using comprehensive measuresâ€”beyond just fatigueâ€”to assess the true impact of potential therapies.
- **Simple Summary:**
A trial found that taking the supplement Oxaloacetate (OAA) ðŸ’Š was linked to better thinking abilities and a slight increase in standing time for people with ME/CFS. Researchers also discovered a strong connection between how tired a person felt and how much their thinking improved when taking the supplement. This work suggests that supplements focusing on the body's energy pathways are a promising area for future treatment research.

</details>


